Get started
Author

Hernán Javier Cutuli

Observed names: H. Cutuli, H.J. Cutuli, Hernan Cutuli, Hernan J Cutuli, Hernan J. Cutuli, Hernan Javier Cutuli, Hernán Cutuli, Hernán J Cutuli
OpenAlex ID: A5113849902
Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer
2023 · J.W.F. Catto, B. Tran, et al. · Annals of Oncology · 84
PDF
Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial
2024 · Robert J. Motzer, Axel Bex, et al. · Journal of Clinical Oncology · 32
Subcutaneous versus intravenous nivolumab for renal cell carcinoma
2024 · L. Albiges, M.T. Bourlon, et al. · Annals of Oncology · 31
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study
2023 · Ondřej Fiala, Sebastiano Buti, et al. · Cancer Immunology Immunotherapy · 28
PDF
First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study
2024 · Talal El Zarif, Karl Semaan, et al. · European Urology · 26
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial
2023 · Nobuaki Matsubara, Ronald de Wit, et al. · European Urology · 26
PDF
First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study.
2022 · Yohann Loriot, Petros Grivas, et al. · Journal of Clinical Oncology · 19
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study
2024 · Francesco Massari, Matteo Santoni, et al. · Cancer Immunology Immunotherapy · 16
PDF
Access of patients with breast and lung cancer to chemotherapy treatment in public and private hospitals in the city of Buenos Aires
2019 · Gonzalo Recondo, César Cosacow, et al. · International Journal for Quality in Health Care · 15
PDF
Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial.
2024 · Robert J. Motzer, Axel Bex, et al. · Journal of Clinical Oncology · 14
PDF
Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial.
2023 · Robert J. Motzer, Paul Russo, et al. · Journal of Clinical Oncology · 9
PIVOT IO 009: A phase 3, randomized study of neoadjuvant and adjuvant nivolumab (NIVO) plus bempegaldesleukin (BEMPEG; NKTR-214) versus NIVO alone versus standard of care (SOC) in patients (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin (cis)-ineligible.
2022 · Petros Grivas, Michiel Simon Van Der Heijden, et al. · Journal of Clinical Oncology · 9
Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti–PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study.
2026 · Robert J. Motzer, Se Hoon Park, et al. · Journal of Clinical Oncology · 8
PDF
1835P A prospective study to determine the prevalence of DNA repair defects in patients (pts) with advanced prostate cancer (PC)
2023 · S.K. Sandhu, G. Gotto, et al. · Annals of Oncology · 8
PDF
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial
2025 · Karim Fizazi, Fred Saad, et al. · The Lancet Oncology · 5
Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Pharmacokinetics (PK), efficacy, and safety results from CheckMate 67T.
2024 · Saby George, Maria Teresa Bourlon, et al. · Journal of Clinical Oncology · 5
Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy
2022 · Angelika Terbuch, Florian Posch, et al. · International Journal of Radiation Oncology*Biology*Physics · 5
PDF
Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial
2026 · Robert J Motzer, Robert J Motzer, et al. · The Lancet · 3
RC48G001: A phase 2 study of disitamab vedotin in HER2-expressing previously treated advanced UC.
2026 · Thomas Powles, Vadim S. Koshkin, et al. · Journal of Clinical Oncology · 3
PDF
Subcutaneous (SC) nivolumab (NIVO) vs intravenous (IV) NIVO in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Safety and patient-reported outcomes (PROs) of the randomized phase 3 CheckMate 67T trial.
2024 · Maria T. Bourlon, Laurence Albiges, et al. · Journal of Clinical Oncology · 3
The Impact of Fibroblast Growth Factor Receptor Alterations in Clinical Outcomes of Patients With Advanced Urothelial Carcinoma: Real-World Data From a Latin American Population
2024 · Vinicius Carrera Souza, Fernando Sabino Marques Monteiro, et al. · Clinical Genitourinary Cancer · 2
Subcutaneous nivolumab versus intravenous nivolumab in patients with previously treated, advanced, or metastatic clear cell renal cell carcinoma.
2022 · Matias Rodrigo Chacon, Hernan J. Cutuli, et al. · Journal of Clinical Oncology · 2
Interim analysis results from Duravelo-2: Zelenectide pevedotin (zele; BT8009) in patients (pts) with previously treated locally advanced/metastatic urothelial carcinoma (la/mUC).
2026 · Daniel P. Petrylak, Mauricio Burotto, et al. · Journal of Clinical Oncology · 1
PDF
Gemcitabine intravesical system (Gem-iDRS) in combination with cetrelimab (CET) versus chemoradiotherapy (CRT) in muscle-invasive bladder cancer (MIBC): SunRISe-2 final results.
2026 · Andrea Necchi, Stephen B. Williams, et al. · Journal of Clinical Oncology · 1
PDF
Circulating tumor DNA levels and related kinetics as prognostic biomarkers for clinical outcomes in mCRPC: A post hoc analysis of CM 7DX.
2025 · Karim Fizazi, Fred Saad, et al. · Journal of Clinical Oncology · 1
PDF
Works count: 45
Citation count: 446
H-index: 11
I10-index: 11
Year
Topic
Type